17Sep 2016

EVALUATION OF THE POTENTIAL OF INTERLEUKIN-9 EXPRESSION AS A PROGNOSTIC FACTOR FOR CHRONIC LYMPHOCYTIC LEUKEMIA IN A COHORT OF EGYPTIAN PATIENTS

  • Clinical pathology department, Faculty of Medicine, Alexandria University, Egypt.
  • Clinical hematology department, Faculty of Medicine, Alexandria University, Egypt
  • .
  • Abstract
  • Cite This Article as
  • Corresponding Author

Chronic lymphocytic leukemia (CLL) is a common lymphoid malignancy that has a highly variable clinical course. Genomic features as zeta-chain-associated protein kinase 70 (ZAP70) expression and CD38 expression provide further differentiation of disease prognosis. Extensive studies have confirmed the oncogenic activities of IL-9 in lymphoma. The aim of the current study was to investigate the contribution of IL-9 expression to the pathogenesis of CLL and its correlation to other prognostic parameters. This study was conducted on 80 patients at diagnosis with CLL and 80 healthy controls. Using real time polymerase chain reaction and enzyme linked immunosorbant assay, IL-9 mRNA expression and its serum level were compared between patients and controls. They were both correlated with other prognostic factors. There was an overexpression of IL-9 in CLL patients that correlated with modified Rai staging, ZAP70, CD38 and all hallmarks of an active and aggressive disease. The correlation between IL-9 upregulation and patient characteristics provided direct clinical evidence for its contribution to the pathogenesis of CLL. In conclusion, significantly higher expression of IL -9 measured at both the mRNA and the protein levels in patients with CLL that correlates with a more complex course of the disease and worse prognosis may allow one to speculate its importance in the pathogenesis of the disease and its possible impact on prognosis.


[Hadeer A Abbassy, Reham A Aboelwafa and Omar M Ghallab. (2016); EVALUATION OF THE POTENTIAL OF INTERLEUKIN-9 EXPRESSION AS A PROGNOSTIC FACTOR FOR CHRONIC LYMPHOCYTIC LEUKEMIA IN A COHORT OF EGYPTIAN PATIENTS Int. J. of Adv. Res. 4 (Sep). 106-112] (ISSN 2320-5407). www.journalijar.com


Hadeer Abbassy


DOI:


Article DOI: 10.21474/IJAR01/1464      
DOI URL: https://dx.doi.org/10.21474/IJAR01/1464